From Dow Jones & Company:

Eli Lilly and Co. sees shares rally to record high after fourth-quarter earnings beat expectations and provide optimistic 2024 revenue outlook. Net income rises to $2.19 billion, or $2.42 a share, from $1.94 billion, or $2.14 a share. Adjusted earnings per share of $2.49 beat FactSet consensus of $2.30. Revenue jumps 28.1% to $9.35 billion, above the FactSet consensus of $8.95 billion. The company expects adjusted EPS of $12.20 to $12.70 and revenue of $40.4 billion to $41.6 billion for 2024. Stock surged 18.7% over the past three months.



Read more: Eli Lilly’s stock surges toward a 5th straight record after an earnings beat and upbeat outlook